521 related articles for article (PubMed ID: 28785879)
1. A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.
Khalilieh SG; Yee KL; Fan L; Liu R; Heber W; Dunzo E; Triantafyllou I; Hussaini A; Iwamoto M
Clin Drug Investig; 2017 Oct; 37(10):975-984. PubMed ID: 28785879
[TBL] [Abstract][Full Text] [Related]
2. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
[TBL] [Abstract][Full Text] [Related]
4. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.
Chen S; Min SS; Peppercorn A; Borland J; Lou Y; Song I; Fujiwara T; Piscitelli SC
Pharmacotherapy; 2012 Apr; 32(4):333-9. PubMed ID: 22422361
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox does not induce QT/QTc-prolongation in healthy subjects.
Sechaud R; Dumortier T; Balez S
Int J Clin Pharmacol Ther; 2009 May; 47(5):321-7. PubMed ID: 19473594
[TBL] [Abstract][Full Text] [Related]
6. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
[TBL] [Abstract][Full Text] [Related]
7. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
[TBL] [Abstract][Full Text] [Related]
8. A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
German P; Mathias A; Brainard DM; Song Q; Ling J; Kearney BP
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):641-651. PubMed ID: 29058821
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
[TBL] [Abstract][Full Text] [Related]
10. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.
Davis JD; Hackman F; Layton G; Higgins T; Sudworth D; Weissgerber G
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):68-75. PubMed ID: 18333868
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravenous zanamivir on cardiac repolarization.
Lou Y; Gan J; Peppercorn A; Gould E; Weller S; Piscitelli SC; Patel P
Pharmacotherapy; 2013 Jul; 33(7):701-9. PubMed ID: 23553534
[TBL] [Abstract][Full Text] [Related]
12. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
13. Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study.
Shen Z; Gillen M; Tieu K; Nguyen M; Harmon E; Wilson DM; Kerr B; Lee CA
Drug Des Devel Ther; 2016; 10():3509-3517. PubMed ID: 27826183
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
[TBL] [Abstract][Full Text] [Related]
15. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
16. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
Abbas R; Hug BA; Leister C; Sonnichsen D
Int J Cancer; 2012 Aug; 131(3):E304-11. PubMed ID: 22065400
[TBL] [Abstract][Full Text] [Related]
17. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
[TBL] [Abstract][Full Text] [Related]
18. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
Darpö B; Sager P; MacConell L; Cirincione B; Mitchell M; Han J; Huang W; Malloy J; Schulteis C; Shen L; Porter L
Br J Clin Pharmacol; 2013 Apr; 75(4):979-89. PubMed ID: 22882281
[TBL] [Abstract][Full Text] [Related]
19. No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.
Vourvahis M; Wang R; Ndongo MN; O'Gorman M; Tawadrous M
Antimicrob Agents Chemother; 2012 May; 56(5):2408-13. PubMed ID: 22371898
[TBL] [Abstract][Full Text] [Related]
20. A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.
Tatosian DA; Cardillo Marricco N; Glasgow XS; DeGroot B; Dunnington K; George L; Gendrano IN; Johnson-Levonas AO; Swearingen D; Kauh E
Clin Pharmacol Drug Dev; 2016 Sep; 5(5):383-92. PubMed ID: 27627194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
